Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
VX-809
Cat No.
CEI-0253
Description
VX-809 can inhibit CFTR with IC 50 of 100 nM.
CAS No.
936727-05-8
Molecular Weight
452.41
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
CFTR
Molecular Formula
C24H18F2N2O5
Chemical Name
3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
Solubility
DMSO 91 mg/mL Water
In vitro
VX-809 is a CFTR corrector that was advanced into clinical development for the treatment of cystic fibrosis. In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approximately 14% of non-CF human bronchial epithelial cells (EC(50), 81 +/- 19 nM), a level associated with mild CF in patients with less disruptive CFTR mutations. F508del-CFTR corrected by VX-809 exhibited biochemical and functional characteristics similar to normal CFTR, including biochemical susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability.
Download
Download Datasheet